EuroBiotech: More Articles of Note

> The U.K drugmaker AstraZeneca said it has penned a deal to sell Germany’s Grünenthal rights to its migraine treatment Zomig for all markets outside of Japan. AZ will get $200 million when the deal is done and up to $102 million in additional payments if targets are hit. FiercePharma story

> Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter. Statement

> Takeda has broken ground on construction of a new €40 million expansion of its production facility in Dublin, Ireland. The high containment production plant will be dedicated to producing Takeda’s blood cancer peptide Ninlaro. Irish Examiner story

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Ipsen has appointed Natixis to purchase 160,000 of its shares, or about 0.2% of the share capital, over the next 2 months. The stock will be allocated to cover its free performance share allocation plan. Release

> In a Joint Declaration published this week and co-signed by European biopharma R&D lobby group EFPIA, 23 EU business signatories are calling on the European Commission, the European Parliament and the Council of the European Union to develop an “ambitious” next EU Research & Innovation Framework Programme. Public letter

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.